PATIENT MONITORING FOR ADULTS WITH PREVIOUSLY TREATED cGVHD

Patient Monitoring1
 

    • Monitor for bleeding and manage
    • Monitor patients for fever and infections, evaluate promptly, and treat
    • Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function
    • Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment. See Dosage and Administration
    • Monitor blood pressure and initiate or adjust anti-hypertensive medication as appropriate and follow dosage modification guidelines for Grade 3 or higher hypertension
    • Check complete blood counts monthly for cytopenias
    • Other malignancies have occurred in patients, including skin cancers and other carcinomas
    • Assess baseline risk for tumor lysis syndrome. Take precautions, monitor, and treat
    • Advise women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy
    • Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose
    • Advise males with female partners of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose
    • Advise women not to breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose

    cGVHD=chronic graft versus host disease.

    Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.